Development of a rational scale to assess the harm of drugs of potential misuse
Drug misuse and abuse are major health problems. Harmful drugs are regulated according
to classification systems that purport to relate to the harms and risks of each drug. However …
to classification systems that purport to relate to the harms and risks of each drug. However …
Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function
V Papadopoulos, M Baraldi, TR Guilarte… - Trends in …, 2006 - cell.com
The peripheral-type benzodiazepine receptor or recognition site (PBR) is a widely
distributed transmembrane protein that is located mainly in the outer mitochondrial …
distributed transmembrane protein that is located mainly in the outer mitochondrial …
Amphetamine, past and present–a pharmacological and clinical perspective
DJ Heal, SL Smith, J Gosden… - Journal of …, 2013 - journals.sagepub.com
Amphetamine was discovered over 100 years ago. Since then, it has transformed from a
drug that was freely available without prescription as a panacea for a broad range of …
drug that was freely available without prescription as a panacea for a broad range of …
Drug harms in the UK: a multicriteria decision analysis
Background Proper assessment of the harms caused by the misuse of drugs can inform
policy makers in health, policing, and social care. We aimed to apply multicriteria decision …
policy makers in health, policing, and social care. We aimed to apply multicriteria decision …
[HTML][HTML] Trial of psilocybin versus escitalopram for depression
R Carhart-Harris, B Giribaldi, R Watts… - … England Journal of …, 2021 - Mass Medical Soc
Background Psilocybin may have antidepressant properties, but direct comparisons
between psilocybin and established treatments for depression are lacking. Methods In a …
between psilocybin and established treatments for depression are lacking. Methods In a …
[HTML][HTML] Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
RL Carhart-Harris, M Bolstridge, J Rucker… - The Lancet …, 2016 - thelancet.com
Background Psilocybin is a serotonin receptor agonist that occurs naturally in some
mushroom species. Recent studies have assessed the therapeutic potential of psilocybin for …
mushroom species. Recent studies have assessed the therapeutic potential of psilocybin for …
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
RL Carhart-Harris, D Erritzoe… - Proceedings of the …, 2012 - National Acad Sciences
Psychedelic drugs have a long history of use in healing ceremonies, but despite renewed
interest in their therapeutic potential, we continue to know very little about how they work in …
interest in their therapeutic potential, we continue to know very little about how they work in …
[HTML][HTML] Increased global integration in the brain after psilocybin therapy for depression
Psilocybin therapy shows antidepressant potential, but its therapeutic actions are not well
understood. We assessed the subacute impact of psilocybin on brain function in two clinical …
understood. We assessed the subacute impact of psilocybin on brain function in two clinical …
[HTML][HTML] Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Rationale Recent clinical trials are reporting marked improvements in mental health
outcomes with psychedelic drug-assisted psychotherapy. Objectives Here, we report on …
outcomes with psychedelic drug-assisted psychotherapy. Objectives Here, we report on …
Neural correlates of the LSD experience revealed by multimodal neuroimaging
RL Carhart-Harris… - Proceedings of the …, 2016 - National Acad Sciences
Lysergic acid diethylamide (LSD) is the prototypical psychedelic drug, but its effects on the
human brain have never been studied before with modern neuroimaging. Here, three …
human brain have never been studied before with modern neuroimaging. Here, three …